Go Pro
NASDAQ:ABVC

ABVC BioPharma (ABVC) Stock Price, News & Analysis

ABVC BioPharma logo
$1.02 +0.01 (+0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 +0.00 (+0.49%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About ABVC BioPharma Stock (NASDAQ:ABVC)

Advanced

Key Stats

Today's Range
$1.00
$1.03
50-Day Range
$1.01
$2.02
52-Week Range
$0.88
$3.40
Volume
36,138 shs
Average Volume
116,168 shs
Market Capitalization
$27.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

AI Generated. May Contain Errors.

ABVC BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

ABVC MarketRank™: 

ABVC BioPharma scored higher than 5% of companies evaluated by MarketBeat, and ranked 880th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    ABVC BioPharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about ABVC BioPharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ABVC BioPharma is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ABVC BioPharma is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ABVC BioPharma has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ABVC BioPharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.21% of the float of ABVC BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ABVC BioPharma has a short interest ratio ("days to cover") of 1.84, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ABVC BioPharma has recently increased by 26.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ABVC BioPharma does not currently pay a dividend.

  • Dividend Growth

    ABVC BioPharma does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ABVC BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    11.38% of the stock of ABVC BioPharma is held by institutions.

  • Read more about ABVC BioPharma's insider trading history.
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABVC Stock News Headlines

ABVC BioPharma Delays Quarterly SEC Filing
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
ABVC BioPharma Reports 2025 Form 10-K
ABVC BioPharma Provides Corporate and Structural Update
See More Headlines

ABVC Stock Analysis - Frequently Asked Questions

ABVC BioPharma's stock was trading at $2.13 at the start of the year. Since then, ABVC shares have decreased by 52.1% and is now trading at $1.02.

ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its quarterly earnings results on Monday, May, 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.

ABVC BioPharma's stock reverse split before market open on Tuesday, July 25th 2023.The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

Last Earnings
5/18/2026
Today
8/06/2026
Next Earnings (Estimated)
8/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ABVC
CIK
1173313
Fax
N/A
Employees
30
Year Founded
2002

Profitability

EPS (Trailing Twelve Months)
($0.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.91 million
Net Margins
N/A
Pretax Margin
-1,143.09%
Return on Equity
-62.46%
Return on Assets
-39.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$510 thousand
Price / Sales
53.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.52 per share
Price / Book
1.96

Miscellaneous

Outstanding Shares
26,550,000
Free Float
21,509,000
Market Cap
$27.08 million
Optionable
Not Optionable
Beta
0.57
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:ABVC) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners